Literature DB >> 10406213

Determination of idarubicin and idarubicinol in rat plasma using reversed-phase high-performance liquid chromatography and fluorescence detection.

O Kuhlmann1, S Hofmann, M Weiss.   

Abstract

A reversed-phase high-performance liquid chromatographic method is described for the simultaneous determination of idarubicin and idarubicinol in rat plasma. Blood samples were analyzed from 16 rats which had received an intravascular dose of 2.25 mg kg(-1) idarubicin. After deproteinization with acetonitrile, the separation was performed with a LiChrospher 100 RP-18 column (5 microm), using fluorescence detection (excitation: 485 nm/emission: 542 nm). The mean recovery was 95.6% for idarubicin and 90.7% for idarubicinol, respectively. The detection limit was 0.25 ng ml(-1) using an injection volume of 50 microl. Daily relative standard deviation (RSD) was 3.2% (10 ng idarubicin/ml, n=10) and 4.4% (10 ng idarubicinol/ml, n=10).

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10406213     DOI: 10.1016/s0378-4347(99)00107-3

Source DB:  PubMed          Journal:  J Chromatogr B Biomed Sci Appl        ISSN: 1387-2273


  4 in total

1.  Pharmacokinetics and toxicity of idarubicin in the rat.

Authors:  O Kuhlmann; S Hofmann; M Weiss
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2001 Oct-Dec       Impact factor: 2.441

2.  Influence of P-glycoprotein modulators on cardiac uptake, metabolism, and effects of idarubicin.

Authors:  W Kang; M Weiss
Journal:  Pharm Res       Date:  2001-11       Impact factor: 4.200

3.  Caffeine enhances myocardial uptake of idarubicin but reverses its negative inotropic effect.

Authors:  Wonku Kang; Michael Weiss
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-01-23       Impact factor: 3.000

4.  Carbon-based ruthenium nanomaterial-based electroanalytical sensors for the detection of anticancer drug Idarubicin.

Authors:  S Irem Kaya; Sevinc Kurbanoglu; Ejmer Yavuz; Sibel Demiroglu Mustafov; Fatih Sen; Sibel A Ozkan
Journal:  Sci Rep       Date:  2020-07-06       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.